Fate Therapeutic Stock Price, News & Analysis

Fate Therapeutics, a clinical-stage biopharmaceutical company, will host a conference call on May 4, 2022, at 5:00 PM ET to discuss its first quarter 2022 financial results and provide a corporate update. Participants can join via phone or listen to the live audio webcast available on the company’s website. Fate Therapeutics is focused on developing first-in-class programmed cellular immunotherapies targeting cancer patients, utilizing its proprietary iPSC product platform for creating off-the-shelf NK and T-cell therapies.

Onxeo S.A. has appointed Dr. Shefali Agarwal as the new President and CEO, succeeding Julien Miara. Dr. Agarwal, previously Chief Medical and Development Officer at Epizyme, has extensive experience in oncology and drug development. The company plans to prepare for a U.S. Pre-IND meeting for its DDR inhibitor, AsiDNA®, and aims to build infrastructure in the U.S. A recent private financing will extend Onxeo's runway into Q2 2023.

Fate Therapeutics (NASDAQ: FATE), a biopharmaceutical firm focused on cellular immunotherapies for cancer, announced its participation in three upcoming investor conferences. These include the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 11:10 AM ET, the Barclays Global Healthcare Conference on March 16, 2022, at 11:45 AM ET, and the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 8:00 AM ET. Each presentation will be available on-demand, with recordings accessible via the Company's website shortly after the events.

Fate Therapeutics reported encouraging clinical progress in its therapies for B-cell malignancies during its Q4 2021 earnings release. The company highlighted a 69% objective response rate (ORR) and 56% complete response (CR) in its FT596+R study. The FDA granted RMAT designation to FT516 for r/r DLBCL, expediting its development. Financially, Fate holds $716.6 million in cash, with Q4 revenue at $17.1 million. However, a projected GAAP loss from operations for 2022 is estimated between $335 million to $365 million, with cash use expected at $290 million to $315 million.

Fate Therapeutics announced plans for a conference call on February 28, 2022, at 5:00 PM ET to discuss its fourth quarter and full year 2021 financial results and provide a corporate update. Interested parties can join via phone or through a live audio webcast accessible on the company's website. Fate Therapeutics specializes in programmed cellular immunotherapies for cancer, leveraging its proprietary induced pluripotent stem cell product platform to develop innovative NK and T-cell therapies.

Fate Therapeutics, a clinical-stage biopharmaceutical firm focused on cellular immunotherapies for cancer, announced upcoming presentations at two investor conferences. The 4th Annual Guggenheim Oncology Day will take place on February 9, 2022, at 11:00 AM ET, followed by the SVB Leerink 2022 Global Healthcare Conference on February 16, 2022, at 3:00 PM ET. Webcasts of these events will be available in the Investors section on their website.

Fate Therapeutics develops universal, off-the-shelf cell therapies using its proprietary iPSC platform.

Fate Therapeutics has received FDA clearance for its Investigational New Drug (IND) application for FT536, an innovative multiplexed-engineered CAR NK cell therapy targeting MICA and MICB stress proteins in solid tumors. The multi-center Phase 1 clinical trial aims to evaluate the treatment's safety and effectiveness as both monotherapy and in combination with monoclonal antibodies. FT536 features a high-affinity CD16 receptor and modified IL-15 components, designed to enhance NK cell activity and persistence in tumor environments. The trial will include various advanced solid tumor types.

Fate Therapeutics (FATE) reported interim Phase 1 data for its FT596 program, focusing on relapsed/refractory B-cell lymphoma. Results show that 5 of 6 patients achieved an objective response, with 4 obtaining a complete response after a single 900 million cell dose combined with rituximab. In total, 13 of 19 patients responded to a single dose of FT596 at lower doses. The treatment was well-tolerated, with no serious adverse events reported. A two-dose regimen is being initiated to assess further efficacy. The company will host a virtual investor event for detailed insights.

Fate Therapeutics presented positive clinical data from its Phase 1 study of FT516 at the 63rd ASH Annual Meeting. The investigational NK cell therapy showed promising results with 6 of 10 CAR T-naïve patients continuing to respond at a median follow-up of 9.1 months. Additionally, 3 of 8 previously treated patients achieved a complete response. FT516 was well-tolerated, with no major safety concerns reported. The FDA granted FT516 RMAT designation, promoting expedited development for relapsed/refractory DLBCL. The company initiated dose-expansion cohorts at 900 million cells per dose, aiming to enroll diverse patient populations.